The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ezhov M.V.

Chazov National Medical Research Center of Cardiology

Shakhnovich R.M.

Federal State Budgetary Institution “National Medical Research Centre of Cardiology Named After academician E.I. Chazov” of the Ministry of Health of the Russian Federation

Alekseeva I.A.

Chazov National Medical Research Center of Cardiology

Pevzner D.V.

Chazov National Medical Research Center of Cardiology

Boytsov S.A.

Chazov National Medical Research Center for Cardiology

Prevalence and role of elevated serum lipoprotein(a) in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI

Authors:

Ezhov M.V., Shakhnovich R.M., Alekseeva I.A., Pevzner D.V., Boytsov S.A.

More about the authors

Journal: Russian Cardiology Bulletin. 2025;20(1): 39‑48

Read: 1467 times


To cite this article:

Ezhov MV, Shakhnovich RM, Alekseeva IA, Pevzner DV, Boytsov SA. Prevalence and role of elevated serum lipoprotein(a) in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Russian Cardiology Bulletin. 2025;20(1):39‑48. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20252001139

Recommended articles:
Fibrin mono­mer in diagnosis of cardiovascular diseases. Russian Cardiology Bulletin. 2024;(4-2):113-120
Myocardial infa­rction in young age. Russian Journal of Preventive Medi­cine. 2024;(11):77-84
Predictors of myocardial infa­rction in patients with stable peri­pheral artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):61-65
Methemoglobinemia with symptoms of acute coro­nary syndrome. Russian Journal of Anesthesiology and Reanimatology. 2025;(1):101-108
Pote­ntial for the use of nutraceuticals for hype­rlipidemia correction. Russian Journal of Preventive Medi­cine. 2025;(3):40-45

References:

  1. Здравоохранение в России 2023. Статистический сборник. Москва 2023, 179 с. 
  2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459-72.  https://doi.org/10.1093/eurheartj/ehx144
  3. Ezhov MV, Kuharchuk VV, Sergienko IV, Alieva AS, Anciferov MB, Ansheles AA, et al. Disorders of lipid metabolism. Clinical guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. In Russian. https://doi.org/10.15829/1560-4071-2023-5471
  4. Kalbacher D, Waldeyer C, Blankenberg S, Westermann D. Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54. Ann Transl Med. 2018;6(16):323.  https://doi.org/10.21037/atm.2018.08.03
  5. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. https://doi.org/10.1093/eurheartj/ehac361
  6. Yang SQ, Liu HX, Yu XQ, Tong L., Chen X., Qi LY, et al. Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome: An observational, retrospective cohort study. Coronary Artery Dis. 2022;33(5):385-393.  https://doi.org/10.1097/MCA.0000000000001134
  7. Welsh P, Welsh C, Celis-Morales CA, Brown R, Ho FK, Ferguson LD, et al. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Eur J Prev Cardiol. 2022;28(18):1991–2000. https://doi.org/10.1093/eurjpc/zwaa063
  8. Bess C, Mehta A, Joshi PH. All we need to know about lipoprotein(a). Prog Cardiovasc Dis. 2024;84:27-33.  https://doi.org/10.1016/j.pcad.2024.05.007
  9. Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953-1975. Epub 2016 Sep 27.  https://doi.org/10.1194/jlr.R071233
  10. Tmoyan NA, Afanasieva MV, Ezhov MV. The role of lipoprotein(a) in the development of atherosclerotic lesions of the peripheral and carotid arteries. Cardiology. 2018;58(6):70–78. Russian. https://doi.org/10.18087/cardio.2018.6.10135
  11. Boytsov SA, Shakhnovich RM, Erlikh AD, Tereschenko SN, Kukava NG, Rytova YuK. et al. Registry of Acute Myocardial Infarction. REGION-MI — Russian Registry of Acute Myocardial Infarction. Kardiologiia. 2021;61(6):41-51.  https://doi.org/10.18087/cardio.2021.6.n1595
  12. Boytsov SA, Shakhnovich RM, Tereschenko SN, Erlikh AD, Pevsner DV, Rytova YuK, et al. Clinical, Anamnestic, and Demographic Characteristics of Patients with Myocardial Infarction in Russian Federation According to the Russian Registry of Acute Myocardial Infarction — REGION–IM. Kardiologiia. 2024;64(4):3-13].
  13. Drapkina OM, Imaeva AE, Kutsenko VA, Kapustina AV, Balanova YuA, Maksimov SA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791. https://doi.org/10.15829/1728-8800-2023-3791
  14. Boytsov SA, Shakhnovich RM, Tereschenko SN, Erlikh AD, Kukava NG, Pevsner DV, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12-22. 
  15. Ezhov MV, Shalnova SA, Yarovaya EB, Kutsenko VA, Evstifeeva SE, Metelskaya VA, Drapkina OM, Boytsov SA. Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases. Arch Med Sci. 2021;19(4):995-1002. https://doi.org/10.5114/aoms/131089
  16. Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2020; 40(1):255-266.  https://doi.org/10.1161/atvbaha.119.312951
  17. Rallidis LS, Pavlakis G, Foscolou A, Kotakos C, Katsimardos A, Drosatos A, Zolindaki M, Panagiotakos DB. High levels of lipoprotein(a) and premature acute coronary syndrome. Atherosclerosis.2018;269:29-34.  https://doi.org/10.1016/j.atherosclerosis.2017.12.011
  18. Varvel S, McConnell JP, Tsimikas S. Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239-2245. https://doi.org/10.1161/ATVBAHA.116.308011
  19. Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, et al; Lp(a)HERITAGE Investigators. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022;9(2):e002060. https://doi.org/10.1136/openhrt-2022-002060
  20. Amiri M, Raeisi-Dehkordi H, Verkaar AJCF, Wu Y, van Westing AC, Berk KA, Bramer WM, Aune D, Voortman T. Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2023;38(5):485-499.  https://doi.org/10.1007/s10654-022-00956-4
  21. https://doi.org/10.34687/2219-8202.JAD.2024.03.0004 
  22. Andreev P, Ezhov M, Khromtsova O, Bykov A, Arkhipov M. Lipoprotein(a) levels distribution in an adult sample from the Middle Ural region. Atherosclerosis. 2024;395:117768. https://www.atherosclerosis-journal.com/article/S0021-9150(24)00336-8/fulltext

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.